In this competing renewal, we propose to continue collaborative studies between the Zlokovic and the Holtzman labs aimed at understanding cellular and molecular mechanisms underlying apolipoprotein E (apoE) effects on the cerebrovascular system, particularly on the blood-brain barrier (BBB), and how these effects contribute to development of neuronal dysfunction and neurodegeneration. Our focus is on apoE/low density lipoprotein receptor related protein-1 (LRP1) interactions in brain capillary endothelium and pericytes that form the BBB in vivo. We propose to study isoform-specific differences in apoE/LRP1 interactions and consequences between apoE4, which is a major genetic risk factor for Alzheimer's disease (AD), and apoE3, which carries a significantly lower risk for AD. Within the neurovascular unit, apoE is produced mainly by astrocytes which allow direct binding, uptake, and signal transduction of astrocyte-derived apoE with cell surface LRP1 expressed in the neighboring pericytes and endothelial cells. LRP1 is a key apoE receptor and an important Alzheimer's amyloid b-peptide (Ab) clearance receptor. Recent studies have suggested that apoE/LRP1 signal transduction in pericytes is important for cerebrovascular integrity. In AD and AD models, LRP1 expression in brain microvessels that form the BBB is significantly reduced. Whether reduced LRP1 expression at the BBB and the resulting diminished apoE-Ab and apoE interactions with LRP1 can initiate Ab, cerebrovascular and neurodegenerative disorders remains, however, unknown. To address these questions we will use new mouse lines with partial or complete LRP1 deletion from endothelium or pericytes generated from conditional Lrp1 mice (Lrp1lox/lox) and crossed with i) 5xFAD (PS/APP);TRE mice with targeted replacement of human apoE gene (TRE) to study Ab-dependent effects, or ii) TRE mice alone to study Ab- independent effects. We will use state-of the art methods to study Ab metabolism, optical imaging methods to study BBB and neurovascular functions ex vivo and in vivo, behavioral tests and methods to study neuronal function and structure. We will determine the effects of LRP1 partial and complete deletion from endothelium and pericytes on Ab pathology, vascular and neurodegenerative changes in aging 5xFAD;TRE3 mice (AIM 1) and 5xFAD;TRE4 mice (AIM 2), and on BBB integrity and neuronal function and structure independently of Ab in aging TRE3 mice (AIM 3) and TRE4 mice (AIM 4). The proposed studies will investigate for the first time the role of diminished LRP1 expression at the BBB, particularly in pericytes and endothelial cells, on apoE isoform- specific effects on disease onset and progression including effects on Ab metabolism and pathology, BBB integrity and neuronal dysfunction and degeneration. We expect that these new findings will establish LRP1 and its Ab-dependent and Ab-independent interactions with apoE in brain endothelium and pericytes as major new therapeutic targets for AD-associated Ab, cerebrovascular and neurodegenerative disorders.

Public Health Relevance

The annual health care costs for neurodegenerative disorders range in excess of a hundred billion dollars. Sadly, we do not have cure yet for any of these diseases. Understanding cellular and molecular mechanisms underlying effects of apolipoprotein E (apoE) on the cerebrovascular system and how these effects may contribute to development of neuronal dysfunction and neurodegeneration will have profound implications for our understanding of Alzheimer's disease pathogenesis and may ultimately guide the development of new therapeutic approaches for this devastating brain disorder.

Agency
National Institute of Health (NIH)
Type
Research Project (R01)
Project #
2R01NS034467-16
Application #
8631776
Study Section
Cell Death and Injury in Neurodegeneration Study Section (CDIN)
Program Officer
Corriveau, Roderick A
Project Start
Project End
Budget Start
Budget End
Support Year
16
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Southern California
Department
Physiology
Type
Schools of Medicine
DUNS #
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Winkler, Ethan A; Sengillo, Jesse D; Sagare, Abhay P et al. (2014) Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. Proc Natl Acad Sci U S A 111:E1035-42
Sagare, Abhay P; Bell, Robert D; Srivastava, Alaka et al. (2013) A lipoprotein receptor cluster IV mutant preferentially binds amyloid-* and regulates its clearance from the mouse brain. J Biol Chem 288:15154-66
Sengillo, Jesse D; Winkler, Ethan A; Walker, Corey T et al. (2013) Deficiency in mural vascular cells coincides with blood-brain barrier disruption in Alzheimer's disease. Brain Pathol 23:303-10
Bell, Robert D; Zlokovic, Berislav V (2009) Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 118:103-13
Deane, R; Sagare, A; Zlokovic, B V (2008) The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease. Curr Pharm Des 14:1601-5
Bell, Robert D; Sagare, Abhay P; Friedman, Alan E et al. (2007) Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 27:909-18
Sagare, Abhay; Deane, Rashid; Bell, Robert D et al. (2007) Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med 13:1029-31
Deane, Rashid; Zlokovic, Berislav V (2007) Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 4:191-7
Brendza, Robert P; Holtzman, David M (2006) Amyloid-beta immunotherapies in mice and men. Alzheimer Dis Assoc Disord 20:118-23
Deane, Rashid; Sagare, Abhay; Hamm, Katie et al. (2005) IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci 25:11495-503

Showing the most recent 10 out of 38 publications